uniQure (QURE) Shares Outstanding (Diluted Average) (2019 - 2026)
uniQure (QURE) recorded quarterly Shares Outstanding (Diluted Average) of $62.7 million in Q1 2026, up 9.11% quarter-over-quarter from $57.5 million in Q4 2025, and up 18.14% on a YoY basis from $53.1 million in Q1 2025.
uniQure (QURE) Shares Outstanding (Diluted Average) (2019 - 2026) Analysis & Trends
uniQure's Shares Outstanding (Diluted Average) history runs 8 years deep, the most recent figure standing at $62.7 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 18.14% year-over-year to $62.7 million; the TTM figure through Mar 2026 stood at $62.7 million (up 18.14% YoY), while the FY2025 annual figure was $57.5 million, up 18.2% from the prior year.
- Shares Outstanding (Diluted Average) was $62.7 million for Q1 2026 at uniQure, up from $57.5 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $62.7 million in Q1 2026 to a low of $46.6 million in Q1 2022.
- Historically, Shares Outstanding (Diluted Average) has averaged $50.3 million across 5 years, with a median of $48.4 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Diluted Average) decreased 0.63% in 2022, then gained 18.2% in 2025.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $46.7 million in 2022, then advanced by 2.0% to $47.7 million in 2023, then climbed by 2.05% to $48.6 million in 2024, then grew by 18.2% to $57.5 million in 2025, then increased by 9.11% to $62.7 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $62.7 million (Q1 2026), $57.5 million (Q4 2025), and $55.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | uniQure | 2.88 Bn | 2.88 Bn | 3.34 Mn | 62.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62.74 Mn |
| Dec 31, 2025 | 57.50 Mn |
| Sep 30, 2025 | 55.88 Mn |
| Jun 30, 2025 | 54.81 Mn |
| Mar 31, 2025 | 53.11 Mn |
| Dec 31, 2024 | 48.65 Mn |
| Sep 30, 2024 | 48.72 Mn |
| Jun 30, 2024 | 48.62 Mn |
| Mar 31, 2024 | 48.38 Mn |
| Dec 31, 2023 | 47.67 Mn |
| Sep 30, 2023 | 47.77 Mn |
| Jun 30, 2023 | 47.65 Mn |
| Mar 31, 2023 | 47.44 Mn |
| Dec 31, 2022 | 46.74 Mn |
| Sep 30, 2022 | 46.77 Mn |
| Jun 30, 2022 | 46.63 Mn |
| Mar 31, 2022 | 46.60 Mn |
| Dec 31, 2021 | 46.84 Mn |
| Sep 30, 2021 | 46.15 Mn |
| Jun 30, 2021 | 46.93 Mn |